NanoViricides is trading 8.59% down at $1.40 in pre-market with no clear company-specific catalyst identified after a sharp move lower from its $1.53 close on July 23, 2026.
- No major company-specific news, earnings releases, or FDA updates were found to explain the downward movement.
- The decline suggests stock-specific selling pressure or a delayed reaction to prior volatility, especially as the broader market is currently trading modestly higher.